Search

Wilson's disease is a genetic disorder that causes excessive accumulation of copper in the body, leading to toxic damage, especially in the liver and nervous system. The current treatment cause burdensome side effects. We describe the use of chemically modified biopolymer carriers based on microcrystalline cellulose and chitosan containing the highly specific copper chelator 8-hydroxyquinoline as a new type of therapy for Wilson's disease. The chelators can scavenges copper ions released from food during digestion and copper ions present in secretions in the gastrointestinal tract. Because the chelator is covalently bound to indigestible biopolymer carriers (crosslinked chitosan or modified cellulose), it is not taken up by the gastrointestinal tract and it can be eliminated through the feces, avoiding unwanted side effects. This concept was tested on Wistar rats, which received a radioactive 64 CuCl 2 solution together with the polymers with covalently bound 8-hydroxyquinoline through a gastric probe. 64 Copper complex uptake from the gastrointestinal tract was significantly inhibited by both chelating polymers. With the modified polymers, the presence of 64 Cu was detected mostly in the gastrointestinal tract, not in the internal organs. These findings indicate modified cellulose and crosslinked chitosan, with covalently bound 8-hydroxyquinoline exhibited the potential to be excellent therapeutics for treating Wilson's disease., (Copyright © 2018 Elsevier B.V. All rights reserved.)

A new thermoresponsive system designed for local radiotherapy has been developed. In this system a radionuclide complex is entrapped in a thermoresponsive polymer locally precipitated at body temperature after injection of a polymer-complex solution into the tissue where a therapeutic effect is required. The lifetime of the system is controlled by the rate of polymer hydrolysis, its dissolution and elimination from the body. The thermoresponsive polymer with the cloud temperature (CT) below body temperature is based on copolymers of N-isopropylmethacrylamide with a methacrylamide-type comonomer containing hydrophobic n-alkyls of three different sizes (C(3), C(6) and C(12)) bonded by a hydrolytically labile hydrazone bond. Hydrolysis of hydrazone bond results in a copolymer soluble at body temperature. The copolymer containing 27.5 mole% of the comonomer with the C(6) moiety, which was chosen for further study, has the CT 22 degrees C and its phase separation is complete at 34 degrees C. Polymer dissolution is complete within 48 h at both pH 5.0 or 7.4. The model therapeutic radionuclide, (64)Cu, in the form of its hydrophobic chelate bis(quinolin-8-olato-N,O) [(64)Cu]copper, is efficiently kept hydrophobically entrapped in the phase-separated polymer until the dissolution by hydrolytic degradation is completed.